FIELD: medicine, oncology, biochemistry, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition comprising compound of the formula (I)
exhibiting activity of steroid sulfatase. Composition can be used for treatment of patients with estrone-dependent tumors, in part, breast cancer. EFFECT: enhanced activity of composition. 18 cl, 5 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORS OF STEROID SULFATASE | 1992 |
|
RU2182152C2 |
| PURIFIED STEROID-SULFAMATE COMPOUNDS, ESTRONE-SULFAMATES | 1992 |
|
RU2210574C2 |
| AROMATASE INHIBITORS | 2010 |
|
RU2572244C2 |
| COMPOUND | 2008 |
|
RU2505532C2 |
| SULPHAMATE DERIVATIVES OF BENZOTHIOPHENE AS STEROID SULPHATASE INHIBITORS | 2006 |
|
RU2424237C2 |
| ETHERS AND RELATED COMPOSITIONS AND METHODS | 2016 |
|
RU2731915C2 |
| COMBINATION OF HDA INHIBITOR AND ANTIMETABOLITE | 2007 |
|
RU2469717C2 |
| LIGANDS FOR H-HISTAMINE RECEPTOR | 1999 |
|
RU2214406C2 |
| HYDROXAMATE DERIVATIVES SUITABLE AS DEACETYLASE INHIBITORS | 2001 |
|
RU2302408C2 |
| IMIDAZOLYL-CYCLIC ACETALS, INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | 1998 |
|
RU2221795C2 |
Authors
Dates
2003-06-27—Published
1992-08-28—Filed